Lineage Cell Therapeutics (LCTX) Non-cash Items (2012 - 2026)

Lineage Cell Therapeutics has reported Non-cash Items for 15 years, with the latest figure at $13.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items rose 136456.7% year-over-year to $13.2 million; the trailing twelve-month figure through Mar 2026 stood at $13.2 million (up 136456.7% YoY), and the FY2025 full-year result was $8.0 million, up 33.54% from the prior year.
• Non-cash Items for Q1 2026 stood at $13.2 million, down from $13.9 million in the prior quarter.
• The five-year high for Non-cash Items was $13.9 million in Q4 2025, with the low at $8500.0 in Q2 2025.
• Historically, Non-cash Items has averaged $6.8 million across 5 years, with a median of $8.5 million in 2022.
• Annual changes were most pronounced in 2025 — Non-cash Items tumbled 99.91% — and 2026, when it jumped 136456.7%.
• Lineage Cell Therapeutics' Non-cash Items stood at $1.4 million in 2022, then decreased by 23.24% to $1.0 million in 2023, then jumped by 807.35% to $9.5 million in 2024, then soared by 46.29% to $13.9 million in 2025, then decreased by 4.69% to $13.2 million in 2026.
• The last three Non-cash Items figures came in at $13.2 million (Q1 2026), $13.9 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.